In addition to being a prospective market with strong growth, Bayer Pharma sees India as a hub for innovation, R&D, and potential partnerships, according to the company's top executives. "Our strategy for India in pharmaceuticals is to continue to make significant investments, we believe that India is a growing market with a growing population," said Julio Triana, head of commercial operations, Japan & APAC for Pharma, president and representative director, Bayer Holding. More than 100 individuals are currently employed by Bayer at its new research facility in Hyderabad, and more will be added in the future.
In the fields of data science and analytics, medication research, manufacturing activities, and clinical trial operations, the Hyderabad hub supports the Bayer worldwide team. As it expands its presence in India, the company said it is also open to partnerships with academic institutions, regional authorities, private businesses, and venture capitalists. A record number of clinical studies are being conducted in India by the pharmaceutical giant.
There are now about 16 clinical studies in various stages of development, including phase 2, phase 3, and phase 4, in fields including oncology, women's health, cardiology, and ophthalmology, among others. "We will continue to bring parts of our value chain as our business grows," Triana added. Triana stated that Bayer wants to include the Indian population in its global trials so that it may provide Indians quicker access to cutting-edge pipeline medications.Verquvo, a medication for deteriorating heart failure, and Kerendia, a medication for chronic kidney disease in Type 2 diabetes, were both introduced by Bayer in India. Asundexian, the company's highly awaited blood thinner that prevents thrombosis and strokes, is scheduled to go on sale in 2026. The medication is a newer version of the popular Xarelto (rivaroxaban).
, CDSCO.jpg)
.jpg)